SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

Intel's Xeon 6 promises AI and network breakthroughs amid company struggles

DeepSeek’s AI disruption looms over Nvidia earnings report

Attention shoppers: Walmart trades at a higher multiple than Apple and Microsoft

Mylo’s “AI wingman” helps reignite a fatigued online dating scene

Buzz

Most popular

Daily

Weekly

1

‘It was through their lies that they became multimillionaires’: Charlie Javice fraud trial opens

2

AI won’t replace developers—but it will change who gets hired

3

Tel Aviv real estate reaches new peak at over $45,000 per sqm

4

Adi Dangot Zukovsky joins Ibex Investors as partner following fund’s leadership shift

5

Yad2 now valued at $420 million as investors line up for potential sale

Gamida Cell

5 stories about Gamida Cell

ג'וליאן אדמס מנכ"ל גמידה

Gamida Cell announces $75 million financing with Highbridge Capital Management

The Israeli company is developing and commercializing cures for blood cancers and serious hematologic diseases

Gamida Cell Downprices Shares to Raise $50 Million Nasdaq IPO

28.10.18|Lilach Baumer

The Israel-based biotech company offered its shares at $8, below its previous intention of $13 to $15 per share

נאסד"ק וול סטריט

Novartis-Backed Gamida Downgrades Nasdaq IPO Expectations to $50-$60 Million

18.10.18|Lilach Baumer

The Jerusalem-based biotech company filed for a $69 million initial public offering in September but disclosed no pricing terms

נאסד"ק וול סטריט

Biotech Company Gamida Cell Files for $69 Million Nasdaq IPO

30.09.18|Dror Reich

The Jerusalem-based company develops cellular and immune therapies. Its lead product is a universal bone marrow transplant solution

המדען הראשי ב כלל ביוטכנולוגיה ד"ר ג'וליאן אדמס

Pharma Veteran Julian Adams takes Helm at Gamida Cell

21.11.17|Lilach Baumer

The Novartis-backed company is developing a universal bone marrow transplant solution for patients unable to find a donor